PT1716853E - Utiliza??o de et743 para o tratamento de cancro em seres humanos - Google Patents

Utiliza??o de et743 para o tratamento de cancro em seres humanos Download PDF

Info

Publication number
PT1716853E
PT1716853E PT06014005T PT06014005T PT1716853E PT 1716853 E PT1716853 E PT 1716853E PT 06014005 T PT06014005 T PT 06014005T PT 06014005 T PT06014005 T PT 06014005T PT 1716853 E PT1716853 E PT 1716853E
Authority
PT
Portugal
Prior art keywords
cancers
treatment
human body
human
Prior art date
Application number
PT06014005T
Other languages
English (en)
Portuguese (pt)
Inventor
George Daniel Demetri
Daniel D Von Hoff
Cecilia Guzman
Jos Jimeno
Esteban Cvltkovic
Luis L Pez L Zaro
Jean Louis Misset
Chris Twelves
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9911183.3A external-priority patent/GB9911183D0/en
Priority claimed from GBGB9911346.6A external-priority patent/GB9911346D0/en
Priority claimed from GBGB9918534.0A external-priority patent/GB9918534D0/en
Priority claimed from GBGB9927005.0A external-priority patent/GB9927005D0/en
Priority claimed from GBGB9927106.6A external-priority patent/GB9927106D0/en
Priority claimed from GB0007637A external-priority patent/GB0007637D0/en
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Publication of PT1716853E publication Critical patent/PT1716853E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
PT06014005T 1999-05-13 2000-05-15 Utiliza??o de et743 para o tratamento de cancro em seres humanos PT1716853E (pt)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GBGB9911183.3A GB9911183D0 (en) 1999-05-13 1999-05-13 Treatment of cancers
GBGB9911346.6A GB9911346D0 (en) 1999-05-14 1999-05-14 Treatment of cancers
GBGB9918534.0A GB9918534D0 (en) 1999-08-05 1999-08-05 Treatment of cancers
GBGB9927005.0A GB9927005D0 (en) 1999-11-15 1999-11-15 Treatment of cancers
GBGB9927106.6A GB9927106D0 (en) 1999-11-16 1999-11-16 Cancer treatment
GB0007637A GB0007637D0 (en) 2000-03-29 2000-03-29 Antitumour compound

Publications (1)

Publication Number Publication Date
PT1716853E true PT1716853E (pt) 2011-05-12

Family

ID=27546594

Family Applications (3)

Application Number Title Priority Date Filing Date
PT06014005T PT1716853E (pt) 1999-05-13 2000-05-15 Utiliza??o de et743 para o tratamento de cancro em seres humanos
PT00927584T PT1176964E (pt) 1999-05-13 2000-05-15 Utilização de et743 para o tratamento de cancro
PT06011784T PT1702618E (pt) 1999-05-13 2000-05-15 Utilização de et743 em terapia de combinação com dexametasona para o tratamento de cancro

Family Applications After (2)

Application Number Title Priority Date Filing Date
PT00927584T PT1176964E (pt) 1999-05-13 2000-05-15 Utilização de et743 para o tratamento de cancro
PT06011784T PT1702618E (pt) 1999-05-13 2000-05-15 Utilização de et743 em terapia de combinação com dexametasona para o tratamento de cancro

Country Status (32)

Country Link
US (1) US8119638B2 (enExample)
EP (3) EP1176964B8 (enExample)
JP (2) JP2002544231A (enExample)
KR (1) KR20020019914A (enExample)
CN (2) CN100477993C (enExample)
AR (1) AR028476A1 (enExample)
AT (3) ATE500830T1 (enExample)
AU (2) AU777417B2 (enExample)
BG (1) BG65680B1 (enExample)
BR (1) BR0010531A (enExample)
CA (1) CA2373794C (enExample)
CY (4) CY1105818T1 (enExample)
CZ (1) CZ301482B6 (enExample)
DE (4) DE122008000013I1 (enExample)
DK (3) DK1716853T3 (enExample)
ES (2) ES2294756T3 (enExample)
FR (1) FR08C0013I2 (enExample)
HU (2) HU229866B1 (enExample)
IL (2) IL146434A0 (enExample)
LU (1) LU91418I2 (enExample)
MX (1) MXPA01011562A (enExample)
MY (1) MY164077A (enExample)
NL (1) NL300337I2 (enExample)
NO (2) NO324564B1 (enExample)
NZ (1) NZ515423A (enExample)
PL (1) PL198185B1 (enExample)
PT (3) PT1716853E (enExample)
SI (3) SI1716853T1 (enExample)
SK (1) SK287580B6 (enExample)
TR (1) TR200103819T2 (enExample)
UA (1) UA74782C2 (enExample)
WO (1) WO2000069441A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164077A (en) 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
MXPA02011319A (es) 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
BR0115162A (pt) * 2000-11-06 2003-10-21 Pharma Mar Sa Tratamentos antitumorais eficazes
GB0117402D0 (en) * 2001-07-17 2001-09-05 Pharma Mar Sa New antitumoral derivatives of et-743
EP1435988A4 (en) * 2001-10-19 2008-01-09 Pharmamar Sa IMPROVED USE OF ANTI-TUMORAL COMPOUND IN THE TREATMENT OF CANCER
GB0202544D0 (en) 2002-02-04 2002-03-20 Pharma Mar Sa The synthesis of naturally occuring ecteinascidins and related compounds
GB0312407D0 (en) * 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
GB0324201D0 (en) * 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
PT1689404E (pt) * 2003-11-13 2008-12-15 Pharma Mar Sau Combinação de et-743 com pró-fármacos de fluorouracil para o tratamento do cancro
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
US20080255132A1 (en) * 2003-11-14 2008-10-16 Eric Rowinsky Combination Therapy Comprising the Use of Et-743 and Paclitaxel for Treating Cancer
JP2008505862A (ja) * 2004-07-09 2008-02-28 ファルマ、マール、ソシエダード、アノニマ 予後分子マーカー
PL1827500T3 (pl) * 2004-10-26 2009-09-30 Pharma Mar Sa Pegylowana liposomalna doksorubicyna w kombinacji z ekteinascydyną 743
DK1658848T3 (da) * 2004-10-29 2007-11-26 Pharma Mar Sa Formuleringer omfattende ecteinascidin og et disaccharid
GB0522082D0 (en) * 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
EP2023931A2 (en) * 2006-05-12 2009-02-18 Pharma Mar S.A. Anticancer treatments with a combination of docetaxel and ecteinascidin
AU2008313634A1 (en) * 2007-10-19 2009-04-23 Pharma Mar, S.A. Prognostic molecular markers for ET-743 treatment
US10610529B2 (en) * 2016-02-04 2020-04-07 Jiangsu Hengrui Medicine Co., Ltd. Trabectedin-inclusive injectable pharmaceutical composition for gastrointestinal external use and a method for manufacturing the same
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام
WO2020239478A1 (en) 2019-05-28 2020-12-03 Pharma Mar, S.A. Trabectedin for treating sarcomas based on genomic markers
CN112574234B (zh) * 2019-09-27 2022-05-24 江苏恒瑞医药股份有限公司 一种海鞘素衍生物的制备方法
WO2021209545A1 (en) 2020-04-15 2021-10-21 Ever Valinject Gmbh Composition comprising trabectedin and an amino acid
EP3960177A1 (en) * 2020-08-26 2022-03-02 Anturec Pharmaceuticals GmbH Composition comprising ttf-ngr for use in treating soft-tissue sarcoma
US12303506B2 (en) 2022-01-20 2025-05-20 Extrovis Ag Trabectedin composition

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3774435D1 (de) * 1986-06-09 1991-12-12 Univ Pennsylvania Ekteinascidine 729, 743, 745, 759a, 759b and 770.
US5256663A (en) * 1986-06-09 1993-10-26 The Board Of Trustees Of The University Of Illinois Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith
US5149804A (en) 1990-11-30 1992-09-22 The Board Of Trustees Of The University Of Illinois Ecteinascidins 736 and 722
US5089273A (en) * 1986-06-09 1992-02-18 Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759A, 759B and 770
DE3635711A1 (de) 1986-10-21 1988-04-28 Knoll Ag 5-nitrobenzo(de)isochinolin-1,3-dione, ihre herstellung und verwendung
GB8805268D0 (en) * 1988-03-04 1988-04-07 Glaxo Group Ltd Medicaments
GB9101221D0 (en) * 1991-01-19 1991-02-27 Smithkline Beecham Plc Pharmaceuticals
US5721352A (en) 1991-02-19 1998-02-24 University Of Florida Research Foundation Entomopoxvirus expression system
FR2697752B1 (fr) 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
US5891704A (en) * 1992-11-19 1999-04-06 Anticancer, Inc. Method to produce high levels of methioninase
JPH09503743A (ja) * 1993-05-14 1997-04-15 デポテック コーポレーション 神経学的疾患の治療方法
US5478932A (en) * 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins
US20040059112A1 (en) 1994-02-18 2004-03-25 Rinehart Kenneth L. Ecteinascidins
US5919816A (en) * 1994-11-14 1999-07-06 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents
GB9508195D0 (en) 1995-04-20 1995-06-07 Univ British Columbia Novel biologically active compounds and compositions,their use and derivation
US5721362A (en) * 1996-09-18 1998-02-24 President And Fellows Of Harvard College Process for producing ecteinascidin compounds
WO1998019649A2 (en) * 1996-11-05 1998-05-14 The Children's Medical Center Corporation Methods and compositions for inhibition of angiogenesis
IL123740A0 (en) * 1997-03-28 1998-10-30 Pfizer NK-1 receptor antagonists for the treatment of delayed emesis
US5985876A (en) 1997-04-15 1999-11-16 Univ Illinois Nucleophile substituted ecteinascidins and N-oxide ecteinascidins
DE19720312A1 (de) * 1997-05-15 1998-11-19 Hoechst Ag Zubereitung mit erhöhter in vivo Verträglichkeit
GB9801231D0 (en) * 1997-06-05 1998-03-18 Merck & Co Inc A method of treating cancer
EP1876180A3 (en) 1998-04-06 2009-12-16 The Board Of Trustees Of The University Of Illinois Semi-synthetic ecteinascidins
KR100643092B1 (ko) * 1998-05-11 2006-11-10 파르마 마르, 에스.에이. 엑테인아시딘 743의 대사산물
US6124292A (en) 1998-09-30 2000-09-26 President And Fellows Of Harvard College Synthetic analogs of ecteinascidin-743
MY164077A (en) 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
AR035842A1 (es) 1999-05-14 2004-07-21 Pharma Mar Sa Metodo de hemisintesis para la formacion de compuestos intermediarios y derivados y de estructuras relacionadas con la ecteinascidina y de tetrahidroisoquinolinfenoles y compuestos intermediarios de aplicacion en dicho metodo
MXPA02010088A (es) 2000-04-12 2004-08-19 Pharma Mar Sa Derivados de ecteinascidina antitumorales.
US7247892B2 (en) 2000-04-24 2007-07-24 Taylor Geoff W Imaging array utilizing thyristor-based pixel elements
MXPA02011319A (es) 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
US7420051B2 (en) 2000-05-15 2008-09-02 Pharma Mar, S.A. Synthetic process for the manufacture of an ecteinaschidin compound
JP2004506430A (ja) 2000-08-11 2004-03-04 シティ・オブ・ホープ Ｓｘｒによるトランス活性化の抗新生物剤ｅｔ−７４３による阻害
BR0115162A (pt) 2000-11-06 2003-10-21 Pharma Mar Sa Tratamentos antitumorais eficazes
EP1360337A1 (en) 2001-02-09 2003-11-12 The Regents Of The University Of California Ecteinascidin family compounds: compositions and methods
US20030027799A1 (en) 2001-03-30 2003-02-06 Shire Biochem Inc. Methods of treating cancer using a combination of drugs
GB0121285D0 (en) 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
EP1435988A4 (en) 2001-10-19 2008-01-09 Pharmamar Sa IMPROVED USE OF ANTI-TUMORAL COMPOUND IN THE TREATMENT OF CANCER
US20040019027A1 (en) 2002-04-12 2004-01-29 Barry Forman Method of treating cerebrotendinous xanthomatosis
GB0312407D0 (en) 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
GB0324201D0 (en) 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
PT1689404E (pt) 2003-11-13 2008-12-15 Pharma Mar Sau Combinação de et-743 com pró-fármacos de fluorouracil para o tratamento do cancro
GB0326486D0 (en) 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
US20080255132A1 (en) 2003-11-14 2008-10-16 Eric Rowinsky Combination Therapy Comprising the Use of Et-743 and Paclitaxel for Treating Cancer
JP2008505862A (ja) 2004-07-09 2008-02-28 ファルマ、マール、ソシエダード、アノニマ 予後分子マーカー
JP2008514688A (ja) 2004-09-29 2008-05-08 ファルマ・マル・エス・アー， ソシエダッド・ユニペルソナル 抗炎症剤としてのエクテイナシジン化合物
PL1827500T3 (pl) 2004-10-26 2009-09-30 Pharma Mar Sa Pegylowana liposomalna doksorubicyna w kombinacji z ekteinascydyną 743
DK1658848T3 (da) 2004-10-29 2007-11-26 Pharma Mar Sa Formuleringer omfattende ecteinascidin og et disaccharid
CA2630900A1 (en) 2005-11-25 2007-05-31 University Of Medicine And Dentistry Of New Jersey Use of parp-1 inhibitors
EP2023931A2 (en) 2006-05-12 2009-02-18 Pharma Mar S.A. Anticancer treatments with a combination of docetaxel and ecteinascidin

Also Published As

Publication number Publication date
AU2005200180B2 (en) 2007-12-13
DE60036826D1 (de) 2007-11-29
ES2272279T3 (es) 2007-05-01
CN1360503A (zh) 2002-07-24
IL146434A (en) 2008-03-20
EP1176964B8 (en) 2007-10-10
HUP0201187A2 (en) 2002-09-28
CA2373794A1 (en) 2000-11-23
IL146434A0 (en) 2002-07-25
AU4597500A (en) 2000-12-05
ES2294756T3 (es) 2008-04-01
JP5777562B2 (ja) 2015-09-09
CZ20014081A3 (cs) 2002-11-13
AR028476A1 (es) 2003-05-14
EP1716853A3 (en) 2006-11-15
AU2005200180B9 (en) 2008-05-29
US8119638B2 (en) 2012-02-21
JP2012149095A (ja) 2012-08-09
CY2008007I2 (el) 2009-11-04
SI1702618T1 (sl) 2008-02-29
PL198185B1 (pl) 2008-06-30
LU91418I9 (enExample) 2019-01-02
EP1702618A3 (en) 2006-12-27
ATE338552T1 (de) 2006-09-15
BR0010531A (pt) 2002-06-04
DE60030554T8 (de) 2008-01-10
EP1716853B1 (en) 2011-03-09
HUP0201187A3 (en) 2002-11-28
HU229866B1 (en) 2014-10-28
AU2005200180A1 (en) 2005-02-10
DE60030554D1 (de) 2006-10-19
CY2008007I1 (el) 2009-11-04
EP1716853A2 (en) 2006-11-02
EP1702618A2 (en) 2006-09-20
NO2008005I1 (no) 2008-06-09
JP2002544231A (ja) 2002-12-24
DE60036826T2 (de) 2008-08-28
ATE375795T1 (de) 2007-11-15
MXPA01011562A (es) 2002-07-30
KR20020019914A (ko) 2002-03-13
DE60030554T2 (de) 2007-09-13
BG65680B1 (bg) 2009-06-30
CY1112753T1 (el) 2016-02-10
CZ301482B6 (cs) 2010-03-17
ATE500830T1 (de) 2011-03-15
NO2008005I2 (enExample) 2010-09-27
CN1679631A (zh) 2005-10-12
NL300337I2 (nl) 2008-09-01
BG106171A (en) 2002-06-28
EP1716853B9 (en) 2011-09-28
CY1107143T1 (el) 2010-07-28
UA74782C2 (uk) 2006-02-15
SI1716853T1 (sl) 2011-10-28
CN100477993C (zh) 2009-04-15
CA2373794C (en) 2005-10-11
NL300337I1 (nl) 2008-05-01
EP1176964A1 (en) 2002-02-06
SK16442001A3 (sk) 2002-03-05
DE60045720D1 (de) 2011-04-21
NZ515423A (en) 2004-04-30
FR08C0013I1 (enExample) 2008-05-30
DK1716853T3 (da) 2011-06-27
AU777417B2 (en) 2004-10-14
SK287580B6 (sk) 2011-03-04
NO324564B1 (no) 2007-11-19
EP1176964B1 (en) 2006-09-06
LU91418I2 (fr) 2008-05-13
HUS1500001I1 (hu) 2016-08-29
EP1702618B1 (en) 2007-10-17
PT1702618E (pt) 2008-01-11
FR08C0013I2 (fr) 2009-10-30
US20070275942A1 (en) 2007-11-29
TR200103819T2 (tr) 2002-04-22
MY164077A (en) 2017-11-30
DK1176964T3 (da) 2007-01-15
DK1702618T3 (da) 2008-02-25
PT1176964E (pt) 2007-01-31
DE122008000013I1 (de) 2008-08-07
NO20015516D0 (no) 2001-11-12
NO20015516L (no) 2002-01-11
WO2000069441A1 (en) 2000-11-23
SI1176964T1 (sl) 2007-02-28
PL352931A1 (en) 2003-09-22
CY1105818T1 (el) 2011-02-02

Similar Documents

Publication Publication Date Title
PT1716853E (pt) Utiliza??o de et743 para o tratamento de cancro em seres humanos
GB9903841D0 (en) Diagnosis and treatment of cancer
HUP0200763A2 (en) Compositions for the treatment and diagnosis of breast cancer and methods for their use
IL151890A0 (en) Hydroxyphenyl-piperidin 4-ylidene-methyl-benzamide derivatives for the treatment of pain
GB2367010B (en) Body treatment product
IL151891A0 (en) Quinolinyl-piperidin 4-ylidene-methyl-benzamide derivatives for the treatment of pain
IL151765A0 (en) Hydroxyphenyl-piperazinyl-methyl-benzamide derivatives for the treatment of pain
GB9811598D0 (en) Diagnosis and treatment of cancer
PL350863A1 (en) Compositions and methods for the treatment and diagnosis of breast cancer
AU9402401A (en) Treatment of cancers
IL149281A0 (en) Treatment of cancer
GB9908059D0 (en) Diagnosis and treatment of diseases
GB9713189D0 (en) Appliance for the beauty treatment of parts of the human body
GB0020261D0 (en) Therapeutic treatment
GB9911183D0 (en) Treatment of cancers
IL133342A0 (en) Electrostatic stimulation of the human body
GB9911346D0 (en) Treatment of cancers
GB9927005D0 (en) Treatment of cancers
GB9918534D0 (en) Treatment of cancers
GB9901904D0 (en) RTherapeutic use of human pheramones
GB9927006D0 (en) Aplidine treatment of cancers
IL145242A0 (en) Treatment of hiatial hernia
GB9907649D0 (en) Skin treatment
GB9904918D0 (en) Skin treatment
GB9911614D0 (en) Body treatment product